Ascendis Pharma A/S (NASDAQ:ASND) Receives Average Rating of "Buy" from Analysts

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) has received an average recommendation of "Buy" from the fourteen research firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation, twelve have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $187.08.

A number of brokerages recently commented on ASND. StockNews.com upgraded shares of Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a research report on Thursday. TD Cowen reduced their price objective on shares of Ascendis Pharma A/S from $175.00 to $157.00 and set a "buy" rating for the company in a research report on Wednesday. Citigroup dropped their target price on shares of Ascendis Pharma A/S from $193.00 to $178.00 and set a "buy" rating for the company in a report on Wednesday. The Goldman Sachs Group increased their target price on shares of Ascendis Pharma A/S from $170.00 to $195.00 and gave the company a "buy" rating in a report on Tuesday, August 13th. Finally, Wells Fargo & Company dropped their target price on shares of Ascendis Pharma A/S from $277.00 to $264.00 and set an "overweight" rating for the company in a report on Wednesday.

Ascendis Pharma A/S Stock Performance

NASDAQ:ASND traded up $0.15 during mid-day trading on Friday, reaching $119.15. The stock had a trading volume of 625,893 shares, compared to its average volume of 393,567. The firm has a market capitalization of $6.94 billion, a price-to-earnings ratio of -12.40 and a beta of 0.63. Ascendis Pharma A/S has a twelve month low of $85.29 and a twelve month high of $161.00. The business has a 50 day simple moving average of $134.38 and a 200 day simple moving average of $138.20.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ASND. Profund Advisors LLC grew its stake in Ascendis Pharma A/S by 3.0% in the 2nd quarter. Profund Advisors LLC now owns 2,919 shares of the biotechnology company's stock worth $398,000 after acquiring an additional 85 shares during the period. EverSource Wealth Advisors LLC grew its stake in Ascendis Pharma A/S by 37.6% in the 4th quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company's stock worth $42,000 after acquiring an additional 91 shares during the period. GAMMA Investing LLC grew its stake in Ascendis Pharma A/S by 52.0% in the 1st quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company's stock worth $45,000 after acquiring an additional 102 shares during the period. Rhumbline Advisers grew its stake in Ascendis Pharma A/S by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company's stock worth $209,000 after acquiring an additional 143 shares during the period. Finally, Quadrant Capital Group LLC grew its stake in Ascendis Pharma A/S by 90.4% in the 4th quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company's stock worth $40,000 after acquiring an additional 151 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.